Biotechnology:

Pharmalicensing
Management Report  December 2006

Today early-stage partnering is a core component of both biotech and pharmaceutical business strategy, allowing companies to access promising new and emerging compounds and technologies. To become a successful player within the life science industry it is crucial to understand the changing dynamics of the industry’s early stage deal-making trends.

Pharmalicensing’s revised second edition of “Early Stage and Discovery Deals: Strategy, Structure and Payment Terms” analyzes the early stage dealmaking trends and discusses the basics of dealmaking structures, covering payments terms and deal valuations.

Updated with new data including case studies from 2006 and contracts this report aims to assist and guide leading professionals involved in business development through the complex process of early stage dealmaking.

Order this report to
   • Discover the benefits of early stage partnering
   • Examine the current partnering model
   • Uncover ways to find the right partner
   • Accumulate tips for structuring and maintaining the right deal
   • Understand the cost differences between in-licensed projects and in-house pre-clinical projects

Report sections include
   • Extensive selections of case studies from 2006, featuring companies such as Amgen AstraZeneca, GlaxoSmithKline  
   • A Comprehensive presentation of headline deal values at different phases of early stage development
   • Detailed company contracts, highlighting real values and information

For full details, please email jenniferc@cmsinfo.com

Order Form

For more information about us, visit CMSinfo.